Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Epidermal Growth Factor Receptor. Found 22 abstracts

no pagination
Ali SM, Alpaugh RK, Buell JK, Stephens PJ, Yu JQ, Wu H, Hiemstra CN, Miller VA, Lipson D, Palmer GA, Ross JS, Cristofanilli M. Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib. Clin Breast Cancer. 2014 Feb;14(1):e14-6.
Astsaturov I, Ratushny V, Sukhanova A, Einarson MB, Bagnyukova T, Zhou Y, Devarajan K, Silverman JS, Tikhmyanova N, Skobeleva N, Pecherskaya A, Nasto RE, Sharma C, Jablonski SA, Serebriiskii IG, Weiner LM, Golemis EA. Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Science signaling. 2010 Jan;3(140):ra67.   PMCID: PMC2950064
Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S, Cora EM, Anderson E, Magill PJ. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clinical Cancer Research. 2010 Mar 15;16(6):1904-14.   PMCID: NIHMS352308
Li L, Quang TS, Gracely EJ, Kim JH, Emrich JG, Yaeger TE, Jenrette JM, Cohen SC, Black P, Brady LW. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J Neurosurg. 2010 Aug;113(2):192-8.   PMCID: not NIH funded
Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS. Targeting EGFR resistance networks in head and neck cancer. Cell Signal. 2009 Aug;21(8):1255-68.   PMCID: PMC2770888
Schilder RJ, Sill MW, Lee YC, Mannel R. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2009 Jul;19(5):929-33.   PMCID: PMC2722934
Astsaturov I, Cohen RB, Harari PM. Clinical application of EGFR inhibitors in head and neck squamous cell cancer. Cancer Treat Res. 2008 Jan;139:135-52.
Borghaei H, Langer CJ, Millenson M, Ruth KJ, Litwin S, Tuttle H, Seldomridge JS, Rovito M, Mintzer D, Cohen R, Treat J. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. J Thorac Oncol. 2008 Nov;3(11):1286-92.
Langer CJ. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer. 2008 Jun 15;112(12):2635-45.
Mehra R, Cohen RB, Harari PM. EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Current oncology reports. 2008 Mar;10(2):176-84.
Sengupta S, Jordan VC. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. Adv Exp Med Biol. 2008 Jan;630:206-19.
Ariazi EA, Kraus RJ, Farrell ML, Jordan VC, Mertz JE. Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway. Molecular cancer research : MCR. 2007 Jan;5(1):71-85.
Astsaturov I, Cohen RB, Harari P. EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets. 2007 Nov;7(7):650-65.
Denlinger CS, Cohen SJ. Progress in the development of prognostic and predictive markers for gastrointestinal malignancies. Current treatment options in oncology. 2007 Oct;8(5):339-51.
Forastiere AA, Burtness BA. Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions. J Clin Oncol. 2007 Jun;25(16):2152-5.
Langer CJ. Mind your elders: therapeutic implications of epidermal growth factor receptor inhibition in older patients with advanced non-small-cell lung cancer. J Clin Oncol. 2007 Mar;25(7):751-3.
Kim SH, Nakagawa H, Navaraj A, Naomoto Y, Klein-Szanto AJ, Rustgi AK, El-Deiry WS. Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras. Cancer Res. 2006 Nov;66(21):10415-24.
Damjanov N, Meropol NJ. Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled?. Oncology (Williston Park). 2004 Apr;18(4):479-88; discussion 488, 493.
Langer CJ. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. Int J Radiat Oncol Biol Phys. 2004 Mar;58(3):991-1002.
Abdollahi A, Gruver BN, Patriotis C, Hamilton TC. Identification of epidermal growth factor-responsive genes in normal rat ovarian surface epithelial cells. Biochem Biophys Res Commun. 2003 Jul 18;307(1):188-97.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Epidermal Growth Factor Receptor

Epidermal Growth Factor Receptor drug therapy therapeutic use metabolism Monoclonal Antibodies genetics Squamous Cell Carcinoma antagonists & inhibitors Quinazolines Female Head and Neck Neoplasms pathology Middle Aged Antineoplastic Agents Aged Protein Kinase Inhibitors Combined Modality Therapy methods Treatment Outcome pharmacology antagonists & Non-Small-Cell Lung Carcinoma Breast Neoplasms Gene Expression Profiling Adult analysis Lung Neoplasms Estrogen Receptors Neoplasm Drug Resistance Prognosis Signal Transduction Human Survival Rate physiology inhibitors Male secondary erbB-2 Receptor Neoplasm Metastasis Proto-Oncogene Proteins c-akt Apoptosis Drug Delivery Systems 80 and over Aged mortality Clinical Trials as Topic dosage Progesterone Receptors Prospective Studies drug effects Cultured Tumor Cells immunology radiotherapy administration & Epithelial Cells 1-Phosphatidylinositol 3-Kinase Estrogen Receptor alpha Estrogens Messenger RNA RNA Interference Colorectal Neoplasms Tamoxifen Loss of Heterozygosity Non-US Gov't Support Triazoles derivatives Ovarian Neoplasms Cell Size pd [Pharmacology] 0 (cetuximab) Gel Electrophoresis-Two-Dimensional Esophageal Neoplasms Monoclonal) 0 (Antibodies Lactate Dehydrogenases Aneuploidy Glioblastoma Thymidylate Synthase Inflammatory breast cancer Next-generation sequencing Gene Dosage Trastuzumab Endonucleases Inhibitors] ras Genes Ovary Mutation 0 (Quinazolines) Uterine Cervical Neoplasms Nitriles Maximum Tolerated Dose Radioimmunotherapy Antibody-Dependent Cell Cytotoxicity Protein Kinase C Age Factors Lapatinib Guanylate Cyclase blood Electrophoretic Mobility Shift Assay Rats Multivariate Analysis Small Interfering RNA Cytotoxins Cisplatin Quality of Life Genetic Transcription Neoplasm Circulating Cells Postmenopause Adjuvant Radiotherapy Clinical Trials tu [Therapeutic Use] Microsatellite Instability Epidermal Growth Factor Tissue Distribution Presenilin-2 Lymphatic Metastasis Oligonucleotide Array Sequence Analysis Immunohistochemistry Proportional Hazards Models Dacarbazine ai [Antagonists & Inhibitors] Peptide Receptors Protein-Tyrosine Kinase ai [Antagonists & Oncogenes Young Adult Protocols bcl-X Protein Biological Models Paclitaxel Neoplasm Proteins DNA-Binding Proteins Mice etiology Biological Tumor Markers Inbred BALB C Mice 184475-35-2 (gefitinib) cytology 0 (erlotinib) Cultured Cells Transformed Cell Line myc Genes Phosphorylation administration & dosage Medical Oncology Brain Neoplasms Neoplastic Gene Expression Regulation Adenocarcinoma US Gov't Support-PHS Double-Blind Method Her2 Nuclear Receptor Coactivator 2
Last updated on Thursday, November 02, 2017